<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-92177</identifier>
<setSpec>0034-947X</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Early onset MODY diabetes</dc:title>
<dc:description xml:lang="en">MODY diabetes (maturity onset diabetes of the yong), type 3, is one of the monogenic diabetes. It is caused by mutations in the hepatocyte nuclear factor (HNF)-q (alpha) gene mutations. We present the case of a 6 year old girl referred for a hyperglycemia study, with no core symptoms of type 1 diabetes, and with a background of diabetes in the two previous generations. In the glucose overload test (GOT), values were observed within the diabetic range, a rare event at such a young age. Treatment was initiated with insulin in the beginning and them with oral antidiabetics, to decrease the risk of microvascular involvement, which is as high as in type 1 diabetes in type 3 MODY (AU)</dc:description>
<dc:creator>Cid Paris, E</dc:creator>
<dc:creator>López Garrido, P</dc:creator>
<dc:creator>Alija Merillas, M</dc:creator>
<dc:creator>Rubio Jiménez, M. E</dc:creator>
<dc:creator>Jiménez Bustos, J. M</dc:creator>
<dc:creator>Ortigado Matamala, A</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La diabetes MODY (maturity onset diabetes of the Young) tipo 3 es una de las diabetes monogénicas y está causada por mutaciones en los genes del factor nuclear hepático 1 alfa (HNF1-&amp;#945;). Presentamos el caso de una niña de 6 años remitida para estudio de hiperglucemia, sin síntomas cardinales de diabetes tipo 1, y con antecedentes de diabetes en las dos generaciones anteriores. En el test de sobrecarga oral de glucosa (SOG) se objetivan cifras en rango diabético, hecho por frecuente una edad tan temprana. Se inicia tratamiento con insulina en un principio, y posteriormente con antidiabéticos orales, para disminuir el riesgo de afectación microvascular, que en  la MODY tipo 3 es tan alto como en la diabetes tipo 1 (AU)</dc:description>
<dc:source>Rev Esp Pediatr;66(6): 385-387, nov.-dic. 2010. tab</dc:source>
<dc:identifier>ibc-92177</dc:identifier>
<dc:title xml:lang="es">Diabetes MODY tipo 3 de inicio precoz</dc:title>
<dc:subject>^d6096^s22074</dc:subject>
<dc:subject>^d2694</dc:subject>
<dc:subject>^d7124^s22016</dc:subject>
<dc:subject>^d50997^s22033</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d3942^s22033</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:type>article</dc:type>
<dc:date>201012</dc:date>
</metadata>
</record>
</ibecs-document>
